Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt.
Eur J Med Chem. 2019 Jan 15;162:147-160. doi: 10.1016/j.ejmech.2018.10.068. Epub 2018 Nov 2.
Herein we report the design and synthesis of novel N-substituted isatins-SLC-0111 hybrids (6a-f and 9a-l). A structural extension approach was adopted via N-alkylation and N-benzylation of isatin moiety to enhance the tail hydrophobic interactions within the carbonic anhydrase (CA) IX active site. Thereafter, a hybrid pharmacophore approach was utilized via merging the pharmacophoric elements of isatin and SLC-0111 in a single chemical framework. As planned, a substantial improvement of inhibitory profile of the target hybrids (Ks: 4.7-86.1 nM) towards hCA IX in comparison to N-unsubstituted leads IVa-c (Ks: 192-239 nM), was achieved. Molecular docking of the designed hybrids in CA IX active site unveiled, as planned, the ability of N-alkylated and N-benzylated isatin moieties to accommodate in a wide hydrophobic pocket formed by T73, P75, P76, L91, L123 and A128, establishing strong van der Waals interactions. Hybrid 6c displayed good anti-proliferative activity under hypoxic conditions towards breast cancer MDA-MB-231 and MCF-7 cell lines (IC = 7.43 ± 0.28 and 12.90 ± 0.34 μM, respectively). Also, 6c disrupted the MDA-MB-231 cell cycle via alteration of the Sub-G phase and arrest of G-M stage. Additionally, 6c displayed significant increase in the percent of annexinV-FITC positive apoptotic cells from 1.03 to 18.54%. Furthermore, 6c displayed potent VEGFR-2 inhibitory activity (IC = 260.64 nM). Collectively, these data suggest 6c as a promising lead molecule for the development of effective anticancer agents.
在此,我们报告了新型 N-取代色酮-SLC-0111 杂化物(6a-f 和 9a-l)的设计和合成。通过色酮部分的 N-烷基化和 N-苄基化采用了结构扩展方法,以增强碳酸酐酶(CA)IX 活性部位内的尾部疏水相互作用。此后,通过将色酮和 SLC-0111 的药效团元素合并到单个化学结构中,采用了杂合药效团方法。按计划,与 N-未取代的先导物 IVa-c(Ks:192-239 nM)相比,目标杂化物对 hCA IX 的抑制谱有了实质性改善(Ks:4.7-86.1 nM)。设计的杂化物在 CA IX 活性部位的分子对接揭示了,如计划的那样,N-烷基化和 N-苄基化色酮部分能够容纳由 T73、P75、P76、L91、L123 和 A128 形成的宽疏水口袋,建立强范德华相互作用。杂化物 6c 在缺氧条件下对乳腺癌 MDA-MB-231 和 MCF-7 细胞系表现出良好的抗增殖活性(IC = 7.43 ± 0.28 和 12.90 ± 0.34 μM)。此外,6c 通过改变 Sub-G 期和 G-M 期阻滞破坏 MDA-MB-231 细胞周期。此外,6c 使 AnnexinV-FITC 阳性凋亡细胞的百分比从 1.03%显著增加到 18.54%。此外,6c 对 VEGFR-2 表现出很强的抑制活性(IC = 260.64 nM)。总的来说,这些数据表明 6c 是开发有效抗癌药物的有前途的先导分子。